driscoll frederick w top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active driscoll frederick w • rockville md how do i update this listing driscoll frederick w is based out of rockville whalewisdom has at least  insider transactions form  in our database for driscoll frederick w summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from driscoll frederick w enter your email address below and choose submit your email cancel contact info driscoll frederick w  belward campus drive rockville md     business phone  sec sic codebiological products no disgnostic substances recent sec filings  filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free frederick driscoll in north reading ma  intelius sign in people search background check criminal records reverse lookup employee screening identity protection intelius premier reverse lookup people search weve found frederick driscoll weve found  records on frederick driscoll across  states in the united states these states include access phone number address records educational information professional data background checks and more on frederick driscoll with intelius  records found for frederick driscoll in north reading ma name age lived at related to  frederick w driscoll redwood city ca  frederick w driscoll  north reading ma andover ma spring hill fl wakefield ma suzan driscoll john driscoll michael driscoll amy hamilton  frederick m driscoll  melrose ma lexington ma danvers ma fredrick driscoll jessica driscoll margaret driscoll rachel driscoll  results for frederick driscoll have been located in the following states intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here cellectar biosciences adds industry veterans douglas swirsky and frederick driscoll to its board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street cellectar biosciences adds industry veterans douglas swirsky and frederick driscoll to its board of directors globenewswire apr    pm edt madison wis april   globe newswire  cellectar biosciences inc nasdaqclrb an oncologyfocused clinical stage biotechnology company today announces it has appointed douglas j swirsky and frederick w driscoll to its board of directors both fred and doug bring extensive operational and industry experience that should prove invaluable to cellectar as we enter this next phase of the companys development said jim caruso president and ceo of cellectar biosciences we look forward to working with both and benefitting from their contributions douglas j swirsky has served as president and chief executive officer of genvec inc since  and also serves as a member of genvecs board of directors  mr swirsky also currently serves as chairman of the board of fibrocell science inc from  through  he served as senior vice president chief financial officer treasurer and corporate secretary of genvec prior to joining genvec in september  mr swirsky worked at stifel nicolaus where he served as a managing director and the head of life sciences investment banking  previously mr swirsky held investment banking positions at ubs painewebber morgan stanley and legg mason his experience also includes positions in public accounting and consulting he received his undergraduate degree in business administration from boston university and his mba from the kellogg school of management at northwestern university mr swirsky is a certified public accountant and a cfa ® charterholder frederick w driscoll served as chief financial officer at flexion therapeutics flexion from  to  spearheading a successful ipo in   prior to joining flexion he was chief financial officer at novavax inc a publicly traded biopharmaceutical company from  to  previously mr driscoll also served as chief financial officer from  to  and subsequently chief executive officer from  to  at genelabs technologies inc a publicly traded biopharmaceutical and diagnostics company that was acquired by glaxosmithkline and chief executive officer at oxigene inc a biopharmaceutical company from  to   he has also served as chairman of the board and audit committee chair at oxigene and as a member of the audit committee for cynapsus which was sold to sunovion pharmaceuticals in  mr driscoll earned a bachelors degree in accounting and finance from bentley university about cellectar biosciences inc cellectar biosciences is developing phospholipid drug conjugates pdcs designed to provide cancertargeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells cellectars pdc platform is based on the companys proprietary phospholipid ether analogs these novel smallmolecules have demonstrated highly selective uptake and retention in a broad range of cancers cellectars pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging the companys lead therapeutic pdc clr  utilizes iodine a cytotoxic radioisotope as its payload clr  is currently being evaluated under an orphan drug designated phase i clinical study in patients with relapsed or refractory multiple myeloma as well as a phase ii clinical study to assess efficacy in a range of bcell malignancies the company is also developing pdcs for targeted delivery of chemotherapeutics such as paclitaxel clr ptx a preclinicalstage product candidate and plans to expand its pdc chemotherapeutic pipeline through both inhouse and collaborative rd efforts for more information please visit  wwwcellectarcom if you liked this article you might like buy these  stocks now for big breakout gains these stocks are within range of triggering big breakout trades roberto pedone may    am edt  stocks boosting the health care sector higher thestreet highlights  stocks that pushed the health care sector thestreet wire aug    pm edt  stocks driving the drugs industry higher thestreet highlights  stocks that pushed the drugs industry thestreet wire aug    pm edt  stocks pushing the drugs industry lower thestreet highlights  stocks pushing the drugs industry lower today thestreet wire aug    pm edt trending walmart in focus amid horrific human trafficking incident in texas that causes nine deaths fords  mustang will have tear your face off horsepower but also a magical burnout button  stocks to give as gifts  things tesla doesnt want to admit everything you need to know about alphabets most fascinating business advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers cynapsus therapeutics appoints frederick driscoll to its board of directors toronto stock exchangecth english français register sign in cynapsus therapeutics appoints frederick driscoll to its board of directors may    et  source cynapsus therapeutics inc toronto may   globe newswire  cynapsus therapeutics inc “cynapsus” or the “company” nasdaqcyna tsxcth a specialty central nervous system “cns” pharmaceutical company developing and preparing to commercialize a fastacting easytouse sublingual thin film for the ondemand management of debilitating off episodes associated with parkinson’s disease “pd” today announced the appointment of frederick w driscoll to its board of directors effective may   mr driscoll has more than  years of financial management experience with biotechnology and medical device companies  mr driscoll will also serve on cynapsus’ audit committee mr driscoll is currently the chairman of the board of oxigene inc nasdaqoxgn  mr driscoll is also currently the chief financial officer at flexion therapeutics nasdaqflxn where he led a successful  million initial public offering and a  million followon offering prior to flexion he was chief financial officer for novavax where he led a team that secured more than  million through a combination of investment funding and commercial and government contracts he was also instrumental in increasing novavaxs institutional shareholder base expanding analyst coverage and implementing numerous financial reforms that strengthened that companys position prior to novavax mr driscoll served as chief financial officer and subsequently chief executive officer of publiclytraded genelabs technologies inc chief financial officer of private company astraris inc and chief executive officer of oxigene we are excited to have fred join our board his financial management experience in the pharmaceutical industry will be invaluable as cynapsus advances its pivotal phase  clinical program for apl and prepares for commercialization fred’s background will complement the other members of the board as we work together to successfully shape cynapsus future and help change the lives of pd patients struggling with off episodes commented rochelle stenzler chair of the board of cynapsus mr driscoll holds a bachelors degree in accounting and finance from bentley university in waltham massachusetts about cynapsus cynapsus is a specialty cns pharmaceutical company developing and preparing to commercialize a fastacting easytouse sublingual thin film for the ondemand management of debilitating off episodes associated with pd the company has successfully completed a phase  clinical trial for its product candidate apl a sublingual formulation of apomorphine hydrochloride or apomorphine apomorphine is the only molecule approved for acute intermittent treatment of off episodes for advanced pd patients but is currently only approved as a subcutaneous injection in the united states apl is a “turning on” medication designed to rapidly safely and reliably convert a pd patient from the off to the on state while avoiding many of the issues associated with subcutaneous delivery of apomorphine it is designed to convert all types of off episodes including morning off episodes often considered the most difficult to treat cynapsus has initiated its phase  clinical program for apl relying on the abbreviated section b regulatory pathway in the united states and the company intends to submit a new drug application near the end of  or in early  for additional company information please visit our website at wwwcynapsusca for more information about the phase  studies including enrollment criteria please visit the following website httpcthandtrialscynapsusca forwardlooking statements this announcement contains forwardlooking statements within the meaning of applicable securities laws including without limitation the company’s expectation for filing an nda near the end of  or in early  and expectations regarding the company’s clinical and regulatory activities including without limitation the anticipated timing and completion of clinical studies these forwardlooking statements include information about possible or assumed future results of the company’s business financial condition results of operations liquidity plans and objectives in some cases you can identify forwardlooking statements by terminology such as “believe” “may” “estimate” “continue” “anticipate” “intend” “should” “plan” “expect” “predict” “potential” or the negative of these terms or other similar expressions these forwardlooking statements are based on the company’s current expectations and beliefs and inherently involve significant risks and uncertainties actual results and the timing of events could differ from those anticipated in such forwardlooking statements as a result of risks and uncertainties and include but are not limited to those factors identified under the caption “risk factors” in the company’s form k filed with the united states securities and exchange commission the “sec” on march   as amended by amendment no  to form ka filed with the sec on march   and its other filings and reports in the united states with the sec available on the sec’s web site at wwwsecgov and in canada with the various canadian securities regulators which are available online at wwwsedarcom furthermore unless otherwise stated the forwardlooking statements contained in this press release are made as of the date of this press release and the company has no intention and undertakes no obligation to update or revise any forwardlooking statements whether as a result of new information future events changes or otherwise except as required by law neither the nasdaq nor the tsx has approved or disapproved of the contents of this press releasecontact information cynapsus kristen galfetti vice president investor relations   x kgalfetticynapsusca media contact russo partners llc matt middleman   mattmiddlemanrussopartnersllccom related articles other press releases by cynapsus therapeutics inc cynapsus therapeutics obtains final court order and hsr waiting period expires for plan of arrangement with sunovion pharmaceuticals october    cynapsus therapeutics securityholders approve the plan of arrangement with sunovion pharmaceuticals october    iss recommends cynapsus therapeutics securityholders vote for the plan of arrangement september    cynapsus receives fda fast track designation for apl for the treatment of off episodes in patients with parkinson’s disease august    cynapsus announces positive opinion from data and safety monitoring board on phase  parkinson’s disease clinical study allowing for athome titration august    profile cynapsus therapeutics inc   subscribe via rss  subscribe via atom  javascript toronto ontario canada contact data contact information cynapsus kristen galfetti vice president investor relations   x kgalfetticynapsusca media contact russo partners llc matt middleman   mattmiddlemanrussopartnersllccom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved frederick w driscoll  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in frederick w driscoll consultant at flexion therapeutics inc view full profile are you frederick w driscoll claim your profile   sign up for equilar atlas and view frederick w driscolls full profile with equilar atlas you can identify corporate executives in frederick w driscolls network and community follow changes in frederick w driscolls employment and moneyinmotion connect with frederick w driscoll through your network of contacts frederick w driscolls executive work history current consultant flexion therapeutics inc past to view frederick w driscolls complete executive work history sign up now age      sign up for equilar atlas and view frederick w driscolls full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like frederick w driscoll more specifically youll be able to identify corporate executives in frederick w driscolls network and community follow changes in frederick w driscolls employment and moneyinmotion connect with frederick w driscoll through your network of conections view full profile   search for over  executive profiles bio example frederick w driscoll frederick w driscolls connections  sign up now to view frederick w driscolls  connections » patrick j mahaffy dir president and chief executive officer clovis oncology inc penny m heaton former chief medical officer novavax inc rahul singhvi former president and chief executive officer novavax inc raymond j hage former sr vp commercial operations novavax inc russell p wilson former vice president and chief financial officer supernus pharmaceuticals inc timothy j hahn former senior vice president global manufacturing operations novavax inc matthew j pfeffer employee mannkind corporation c ann merrifield lead director invivo therapeutics holdings corp joel t citron board member oasmina pharmaceutical david j chaplin dir chief scientific officer and former chief executive officer oxigene inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla claiborne p deming chairman of the board murphy oil corporation daniel a dematteo executive chairman gamestop corp × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   genelabs technologies inc frederick w driscoll a publisher of business information since         search business search executive   advanced search      sign in    hints company name genelabs technologies inc ticker symbol gnlb  address  penobscot dr redwood city ca  united states email infogenelabscom phone  website wwwgenelabscom fax              summary                   executive details              financial details               board members             stock ownership      subsidiaries business information the groups principal activity is to discover and develop pharmaceutical products the group is currently pursuing regulatory approval of prestara tm its investigational drug for women with systemic lupus erythematosus it is also pursuing the discovery of antiviral compounds for the treatment of hepatitis c virus hcv infections and is advancing its hcv research program into preclinical development in addition the group has established a portfolio of patents and patent applications based on inventions arising from its research and development activities trademarks include prestara tm anastar tm and aslera tm executive information name title email irene chowchmn  genelabs technologies inc na frederick driscollcfo na ronald griffithchief scientific officer na heather kellervp  business strategy sec na kenneth schwartzvp  medical affairs na   financial information   all figures in    year sales net income         to see complete results subscribe now to see complete results subscribe now click for more executives        financial summary                income statement                  balance sheet                   cash flows                    ratios           for subscribers onlyclick here to subscribe now             home    about us    product information     subscription    list builder     executive list     email lists     contact us    site map    browse directory    nbsp   walkerss research  a publisher of business information since  all rights reserved flxn frederick w driscoll insider trades for flexion therapeutics inc bulletin investor alert tokyo markets open in us market snapshot currencies commodities expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close flexion therapeutics inc nasdaq flxn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus flexion therapeutics inc after hours  quotes are delayed by  min jul    pm flxn quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   insider activity individual frederick w driscoll transactions date shares transaction value     disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share                acquisition at  per share      acquisition at  per share            copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr michael d clayman president chief executive officer cfo  director dr yamo deniz chief medical officer dr neil bodick chief scientific officer ms carolyn beaty scimemi chief compliance officer mr dan leblanc senior vice presidentcmc operations dr scott d kelley vice presidentmedical affairs dr adam l muzikant vice presidentbusiness development ms christina willwerth senior vice presidentprogram management mr john magee vice presidentsales mr scott young senior directorcorporate communications  ir ms rose villandry vice presidenthuman resources mr mark s levine secretary senior vp  general counsel ms kerry a wentworth senior vice presidentregulatory affairs  quality mr patrick j mahaffy chairman mr mark p stejbach independent director mr scott a canute independent director mr sandesh mahatme independent director ms c ann merrifield independent director dr heath lukatch independent director mr alan w milinazzo independent director mr samuel d colella independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pfed to stick to plans for rate hike balancesheet selloff this year pmls says no to promotionandrelegation regime — and  billion to boot pbitcoin platform scores key greenlight from wall street regulator palphabet falls after earnings beat live blog recap pis kushners statement a turning point for trump team pis this why united tsa clashed on twitter over comic books on planes pyear treasury yield snaps sixday streak of declines pcompanies do better when ceo pay dwarfs average worker study finds panadarko shares down  after company posts widerthanexpected loss palphabet falls after earnings beat live blog ptrump pushes gop for affordable care act repeal pus will go singlepayer route on health care jimmy carter pthe scientifically proven reason you should stop feeling guilty about ordering takeout pnasdaq closes at record as tech stocks shake off broader weakness pwatch out for these surprise charges at the er phere’s a sign investors are viewing earnings through rosetinted glasses popinion journal congresss russia sanctions calculus popinion journal robert mueller’s power play popinion journal joseph rago popinion journal americans abroad beware loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice